IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy

Stock News

Mar 18

IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced that its self-developed drug, Amurelifup α (IMM0306), has received official approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for the treatment of Primary Membranous Nephropathy (PMN). This marks another significant milestone for IMM0306 in the field of autoimmune kidney diseases, representing a substantial step forward for the innovative drug in nephrology treatment. The company stated that the Phase II clinical approval for IMM0306 in treating PMN, along with the recent development of its subcutaneous injection formulation (IMM0306S), highlights IMMUNEONCO-B's concentrated efforts in the autoimmune disease sector and reflects its strategic progress in achieving multiple breakthroughs across its autoimmune pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127803256"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127803256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127803256?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127803256","market":"hk","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced that its self-developed drug, Amurelifup α (IMM0306), has received official approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for the treatment of Primary Membranous Nephropathy (PMN). This marks another significant milestone for IMM0306 in the field of autoimmune kidney diseases, representing a substantial step forward for the innovative drug in nephrology treatment. The company stated that the Phase II clinical approval for IMM0306 in treating PMN, along with the recent development of its subcutaneous injection formulation (IMM0306S), highlights IMMUNEONCO-B's concentrated efforts in the autoimmune disease sector and reflects its strategic progress in achieving multiple breakthroughs across its autoimmune pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 10:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced that its self-developed drug, Amurelifup α (IMM0306), has received official approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for the treatment of Primary Membranous Nephropathy (PMN). This marks another significant milestone for IMM0306 in the field of autoimmune kidney diseases, representing a substantial step forward for the innovative drug in nephrology treatment. The company stated that the Phase II clinical approval for IMM0306 in treating PMN, along with the recent development of its subcutaneous injection formulation (IMM0306S), highlights IMMUNEONCO-B's concentrated efforts in the autoimmune disease sector and reflects its strategic progress in achieving multiple breakthroughs across its autoimmune pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1127803256","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127803256","pubTimestamp":1773802458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard"},"translate_title":"IMM0306治疗原发性膜性肾病II期临床试验获批后，IMMUNEONCO-B(01541)股价飙升超过10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01541":1},"content_text":"IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced that its self-developed drug, Amurelifup α (IMM0306), has received official approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for the treatment of Primary Membranous Nephropathy (PMN). This marks another significant milestone for IMM0306 in the field of autoimmune kidney diseases, representing a substantial step forward for the innovative drug in nephrology treatment. The company stated that the Phase II clinical approval for IMM0306 in treating PMN, along with the recent development of its subcutaneous injection formulation (IMM0306S), highlights IMMUNEONCO-B's concentrated efforts in the autoimmune disease sector and reflects its strategic progress in achieving multiple breakthroughs across its autoimmune pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}